Targeting RAS signalling pathways in cancer therapy

@article{Downward2003TargetingRS,
  title={Targeting RAS signalling pathways in cancer therapy},
  author={Julian Downward},
  journal={Nature Reviews Cancer},
  year={2003},
  volume={3},
  pages={11-22}
}
  • J. Downward
  • Published 2003
  • Biology, Medicine
  • Nature Reviews Cancer
The RAS proteins control signalling pathways that are key regulators of several aspects of normal cell growth and malignant transformation. They are aberrant in most human tumours due to activating mutations in the RAS genes themselves or to alterations in upstream or downstream signalling components. Rational therapies that target the RAS pathways might inhibit tumour growth, survival and spread. Several of these new therapeutic agents are showing promise in the clinic and many more are being… Expand

Paper Mentions

Interventional Clinical Trial
This is a phase II open label study that will evaluate children ≥ 1 year of age and adults with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the MEK… Expand
ConditionsNeurofibromatosis Type 1, Plexiform Neurofibroma
InterventionDrug
Targeting Ras and Rho GTPases as opportunities for cancer therapeutics.
TLDR
The Ras and Rho GTPases play significant roles in the development of numerous aspects of the malignant phenotype by promoting cell cycle progression, resistance to apoptotic stimuli, neo-vascularisation and tumour cell motility, invasiveness and metastasis. Expand
Targeting the mitogen-activated protein kinase cascade to treat cancer
The RAS–mitogen activated protein kinase (MAPK) signalling pathway has long been viewed as an attractive pathway for anticancer therapies, based on its central role in regulating the growth andExpand
MAP kinase signalling pathways in cancer
TLDR
Recent findings and hypotheses on the role of MAPK pathways in cancer are discussed, with a focus on stress-activated pathways, which largely seem to counteract malignant transformation. Expand
The spatiotemporal regulation of RAS signalling.
TLDR
New insights into the control of spatiotemporal RAS signalling reveal that activation kinetics and subcellular compartmentalisation are tightly coupled to the generation of specific biological outcomes. Expand
Modelling oncogenic Ras/Raf signalling in the mouse.
TLDR
Tractable mouse models will enable the pursuit of basic biological mechanisms and translational applications regarding the MAPK pathway and help in the unravelling of how deregulated MAPK signalling leads to disease. Expand
Oncogene-directed alterations in cancer cell metabolism.
TLDR
Evidence for oncogene-directed cancer metabolic regulation is presented and the importance of identifying underlying mechanisms that can be targeted for developing precision cancer therapies is discussed. Expand
Small molecule inhibitors of RAS proteins with oncogenic mutations
TLDR
This review aimed to collect all of the reported small molecules that affect RAS signalling and discusses direct inhibition; particularly the most recently reported covalent inhibitors, which are already advanced to human clinical trials. Expand
RHO Proteins in RAS Signaling and Transformation
TLDR
How Rho family GTPases relay Ras signaling to downstream components and what roles they serve in Ras-induced oncogenesis will be the subject of this chapter. Expand
Targeting Ras in Myeloid Leukemias
TLDR
General strategies for targeting hyperactive Ras signaling in cancer cells with specific reference to myeloid malignancies are discussed. Expand
The Biology of K-Ras Signaling Pathways in Pancreatic Cancer
TLDR
The evidence, from both in vitro studies and studies using genetic mouse models, of the importance of oncogenic K-Ras and its downstream signaling pathways in driving pancreatic tumor formation and cancer cell growth is described. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 105 REFERENCES
Concepts in Ras-directed therapy.
  • Kloog, Cox, Sinensky
  • Biology, Medicine
  • Expert opinion on investigational drugs
  • 1999
TLDR
A description of a recently described novel drug concept that could restore the defective GTPase activity of oncogenic Ras is described and the interesting results of reovirus-induced tumour regression observed in animal models of human tumours containing an intact Ras signalling pathway are observed. Expand
Development of anticancer drugs targeting the MAP kinase pathway
TLDR
The rationale for targeting the MAP kinase pathway will be reviewed here along with a discussion of various pharmacological approaches and the promise they hold for a new generation of anticancer drugs. Expand
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
TLDR
The discovery of a highly potent and selective inhibitor of the upstream kinase MEK that is orally active is reported, indicating that MEK inhibitors represent a promising, noncytotoxic approach to the clinical management of colon cancer. Expand
Mutations of the BRAF gene in human cancer
TLDR
BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers, with a single substitution (V599E) accounting for 80%. Expand
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
TLDR
CCI-779, an ester analog of rapamycin with improved pharmaceutical properties and aqueous solubility, has demonstrated impressive activity against a broad range of human cancers growing in tissue culture and in human tumor xenograft models, which has supported the development of compounds targetingRapamycin-sensitive signal-transduction pathways. Expand
Epidermal growth factor receptor tyrosine kinase inhibitors.
TLDR
Preclinical pharmacology studies illustrate the potential use of selective small-molecule inhibitors of epidermal growth factor receptor tyrosine kinase activity in combination with chemotherapy, radiotherapy and hormone therapy, and in chemoprevention, in a spectrum of solid human tumours. Expand
Ras and Rho regulation of the cell cycle and oncogenesis.
TLDR
Current knowledge of how deregulated Ras activation alters the function of cyclin D1, p21(Cip1), and p27(Kip1) is summarized and the involvement of Rho small GTPases in cell cycle regulation and the cell-type differences in how Ras signaling interfaces with the cell cycle machinery are emphasized. Expand
Increasing complexity of Ras signaling
TLDR
Current understanding of Ras signal transduction is summarized with an emphasis on new complexities associated with the recognition and/or activation of cellular effectors, and the diverse array of signaling pathways mediated by interaction between Ras and Ras-subfamily proteins with multiple effectors. Expand
Signal transduction via Ras.
TLDR
Structural and mechanistic studies on Ras and its interaction with effectors and GAP will be discussed in the context of the biology and pathophysiology of this protein. Expand
Rational therapeutic intervention in cancer: kinases as drug targets.
  • C. Sawyers
  • Biology, Medicine
  • Current opinion in genetics & development
  • 2002
TLDR
STI-571, a small molecule inhibitor of the Bcr-Abl, c-kit and platelet derived growth factor receptor tyrosine kinases, produced dramatic clinical responses in patients with Bcr/neu positive chronic myeloid leukemia and c/kit positive gastrointestinal stromal tumors, galvanized the cancer research community to extend kinase-inhibitor therapy to other cancers. Expand
...
1
2
3
4
5
...